A Phase I Study of Continuous Infusion Cilengitide in Patients with Solid Tumors

BACKGROUND: Cilengitide (EMD121974) is a cyclized pentapeptide that is a potent and selective integrin antagonist which has shown activity in malignant gliomas. In all previous studies, cilengitide has been administered in an intermittent fashion. However, cilengitide has a short half-life of 3-5 ho...

Full description

Saved in:
Bibliographic Details
Main Authors: O’Donnell, Peter H., Undevia, Samir D., Stadler, Walter M., Karrison, Theodore M., Nicholas, M. Kelly, Janisch, Linda, Ratain, Mark J.
Format: Artigo
Language:Inglês
Published: 2010
Subjects:
Article
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC3059335/
https://ncbi.nlm.nih.gov/pubmed/20839028
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10637-010-9537-9
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items